Add-On Payment Accelerates Commercialization Of NeuroPace’s RNS
This article was originally published in The Gray Sheet
Executive Summary
The company is focused on expanding the number of centers that use its responsive neurostimulator RNS system to treat seizures in patients with epilepsy, while eyeing other indications. It’s also partnering with the Defense Department on a memory restoration project.
You may also be interested in...
Medicare Add-On Payments Granted For Cardiac, Neuro Devices
CMS agreed to grant new tech add-on payments to St. Jude’s CardioMEMS implantable heart failure monitoring system and Abbott’s MitraClip mitral valve repair system, but it took some convincing. The agency also granted an add-on for NeuroPace’s RNS responsive neurostimulator system to treat seizures.
NeuroPace’s RNS For Epilepsy Becomes First FDA-Approved Responsive Neurostimulator
While standard neurostimulators are open-loop systems that stimulate continuously or intermittently according to preprogramming, RNS is a more targeted, closed-loop system that monitors brain activity in real time and provides electrical stimulation to interrupt troubling patterns that might cause a seizure.